Immuneering Corporation (IMRX)

Pancreatic cancer. Standard of care: 8.5 months.
$IMRX
drug: 17.3 months. Doubled survival. Zero drug-related toxicity.
Down 20% this month. Pipeline priced at $82M.

Oppenheimer (Jay Olson): Reiterated Outperform | $30.00 Price Target
Rationale: Jay Olson strongly defended the survival data, viewing the overall survival numbers as highly competitive.

Extremely undervalued here.
Trading at cash after amazing Phase 2 news.

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.
Immuneering’s investigational pancreatic cancer drug gave patients in a mid-stage trial nearly nine additional months of survival—adding another potential weapon to the quickly advancing next-gen treatment arsenal for the deadly disease.

In a Phase 2a trial, the MEK-targeting deep cyclic inhibitor atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) elicited 17.3-months median overall survival (MOS), compared with 8.5 months for patients given gemcitabine/nab-paclitaxel in the pivotal Phase 3 MPACT study. Abraxane (nab-paclitaxel) in combination with gemcitabine, a regimen known as GnP, has been the standard of care for late-stage pancreatic cancer since Abraxane’s approval in 2013.

Median progression-free survival for the atebimetinib/chemotherapy combo was 8.3 months, while the disease control rate was 82%. The confirmed overall response rate was 36%.

The data come from 55 patients with first-line metastatic pancreatic cancer given 320 mg of atebimetinib plus mGnP. Immuneering first reported the overall survival results on May 21 and elaborated on the data Monday in an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting.

These results for atebimetinib follow Revolution Medicines’ groundbreaking pancreatic cancer win, when its RAS inhibitor daraxonrasib doubled survival in the second line setting in a Phase 3 trial whose results were announced in April. In an interview with BioSpace prior to the ASCO presentation, Immuneering CEO Ben Zeskind put the company’s results into the context of the overall pancreatic cancer treatment space.

“We kind of have cancer surrounded,” he said. “Those RAS inhibitors are making a really good attack from the second line direction. We think 17.3 months is a really compelling median overall survival coming from the first-line direction.”

Zeskind also noted the consistency of atebimetinib’s results. In the original 34-patient cohort with a median follow-up of 17 months, MOS was likewise 17.3 months, according to Immuneering’s press release on Monday. “I think [it] really speaks to the robustness of the data,” he said.

Immuneering’s initial recruitment goal for the Phase 2a trial was 30 patients, but “there was just so much demand at our sites” because of what investigators were observing, and “we kind of took as many more patients as we could.”

Tolerability equals survival
Notably, the biotech observed only two categories of Grade 3 or higher treatment-related adverse events in at least 10% of participants—both of which Zeskind said were related to the chemo.

“I think the tolerability is certainly something to highlight,” Meredith Pelster, associate director of gastrointestinal cancer research at the Sarah Cannon Research Institute and an investigator on the Phase 2a trial, told BioSpace. “With the modified gemcitabine/nab-paclitaxel schedule, I’m not having to deal with the degree of cytopenias I typically would, and then the addition of atebimetinib, really we’re not seeing high-grade toxicity at all . . . . Keeping these patients on treatment is not challenging.”

While daraxonrasib appears to be extremely efficacious, it does come with some problematic side effects. The majority of patients on Revolution’s drug develop a rash—a side effect apparent in a recent 60 Minutes interview with former Nebraska Sen. Ben Sasse. Sasse credited daraxonrasib with decreasing his pain and reducing his tumor volume by 76%, USA Today reported, but a rash was evident on his face.

In the Phase 3 RASolute 302 trial, 43.6% of patients on daraxonrasib experienced a grade 3 or higher treatment-related adverse event (TRAE), compared to 57.5% of patients receiving chemo. However, just 1.2% of patients stopped treatment with Revolution’s drug due to these TRAEs.

Immuneering’s results “kind of redefine the tradeoffs” patients have to make, Zeskind said. “It used to be really that patients had to choose between survival and tolerability, between more time and the quality of that time, and I think the possibility that these data raise is that patients may have to make fewer trade-offs.”

Tolerability is not only important for quality of life, Zeskind added, but is also key to survival. When a patient’s status declines to a certain level on a key performance scale, he said, there is around a 48% increase in the risk of death. “Similarly, if they’re so beat up by the first-line therapy that they can’t go on to second-line therapy, in the literature, it’s about a 51% increase in the risk of death.”

In Immuneering’s trial, 84% of participants maintained or gained weight at three months—a particular challenge for patients with pancreatic cancer, according to Zeskind.

“The tolerability, the weight stability and gain, and the median overall survival—these are all, we think, important characteristics for a first-line treatment,” he said.

Notably, Immuneering’s stock began to fall following the data. The company’s shares were down nearly 24% as of 3 pm Eastern time on Monday.

Mizuho analysts, in a midday note, said, “The weakness appears way overdone.”

The firm attributed the “intra-day weakness” to a “slight diminution of the ORR to 36% (vs. 39% previously),” and the news that one patient discontinued treatment with atebimetinib. Having spoken with Immuneering’s management, however, the analysts said they did not have any concerns.

Next up, Immuneering intends to dose the first patient in the Phase 3 MAPKeeper 301 trial around the middle of this year. The biotech is planning to enroll around 510 patients in this study, Zeskind said, and expects to report topline results in mid-2028.

“We’re all very excited,” about the upcoming Phase 3 trial, said Pelster, who will also serve as an investigator on this study. “We need to prove that the combination is superior to standard of care, and when that happens, then we can really get this drug to people to make a difference.”Immuneering’s results “kind of redefine the tradeoffs” patients have to make, Zeskind said. “It used to be really that patients had to choose between survival and tolerability, between more time and the quality of that time, and I think the possibility that these data raise is that patients may have to make fewer trade-offs.”

Tolerability is not only important for quality of life, Zeskind added, but is also key to survival. When a patient’s status declines to a certain level on a key performance scale, he said, there is around a 48% increase in the risk of death. “Similarly, if they’re so beat up by the first-line therapy that they can’t go on to second-line therapy, in the literature, it’s about a 51% increase in the risk of death.”

In Immuneering’s trial, 84% of participants maintained or gained weight at three months—a particular challenge for patients with pancreatic cancer, according to Zeskind.

“The tolerability, the weight stability and gain, and the median overall survival—these are all, we think, important characteristics for a first-line treatment,” he said.

Notably, Immuneering’s stock began to fall following the data. The company’s shares were down nearly 24% as of 3 pm Eastern time on Monday.

Mizuho analysts, in a midday note, said, “The weakness appears way overdone.”

The firm attributed the “intra-day weakness” to a “slight diminution of the ORR to 36% (vs. 39% previously),” and the news that one patient discontinued treatment with atebimetinib. Having spoken with Immuneering’s management, however, the analysts said they did not have any concerns.

Next up, Immuneering intends to dose the first patient in the Phase 3 MAPKeeper 301 trial around the middle of this year. The biotech is planning to enroll around 510 patients in this study, Zeskind said, and expects to report topline results in mid-2028.

“We’re all very excited,” about the upcoming Phase 3 trial, said Pelster, who will also serve as an investigator on this study. “We need to prove that the combination is superior to standard of care, and when that happens, then we can really get this drug to people to make a difference.”


https://www.biospace.com/drug-development/asco-biopharma-has-pancreatic-cancer-surrounded-as-immuneerings-drug-adds-9-quality-months

news: June 1, 2026
PDF Version
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study -

- Only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy related -

- 84% of participants maintained or gained weight at three months -

- Global Phase 3 MAPKeeper 301 trial (NCT07562152) in first-line metastatic pancreatic cancer actively recruiting, with first patient dosing expected in mid-2026 -

https://ir.immuneering.com/news-releases/news-release-details/immuneering-presents-compelling-173-month-median-overall

Ahead of ASCO 2026, Biotech Sector Fixates on Pancreatic Cancer Breakthroughs

Treating pancreatic cancer has long been hampered by the tumor's dense stromal microenvironment, which effectively suffocates immune responses and blocks traditional chemotherapy delivery. However, preliminary data circulating ahead of ASCO suggests that next-generation targeted therapies are finally penetrating this biological fortress.

https://www.bpiq.com/post/asco-2026-preview-10-tickers-to-watch

$IMRX


https://streamlinefeed.co.ke/news/stat-ahead-of-asco-all-eyes-on-pancreatic-cancer

countdown

Encouraged to see @BioWorld spotlight progress in pancreatic cancer.

Atebimetinib, has shown promising survival in 1L PDAC, with 17.3 mth median OS observed in a Ph2a trial when dosed in combination with chemo.

We look forward to sharing a full dataset at #ASCO26. https://t.co/1XUCiRYzxA— Immuneering Corp (@Immuneering) May 27, 2026

https://www.bioworld.com/articles/731386-mek-inhibitor-delivers-173-month-os-for-pancreatic-cancer?v=preview

countdown

In a report released , Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Immuneering, with a price target of $12.00.

Mizuho added—Concurrent with its ASCO abstract released yesterday, in a surprise, IMRX separately announced first-ever median overall survival/mOS data for lead asset atebimetinib/atebi in 1L metastatic pancreatic cancer/PanCa patients.

In a significant positive, IMRX reported an astounding 17.3 months mOS for atebi — easily beating current standard of care treatments.

This data, which comes as a teaser of what will be presented at next week's ASCO meeting, comes from all 55 1L metastatic PanCa patients treated with atebi plus modified gemcitabine + nab-paclitaxel/mGnP in the company's ongoing P2a study.

Full data, including OS, PFS, response, weight stability/cachexia and safety/tolerability will be presented at an oral session at ASCO on June 1, with IMRX also hosting a conference call on the data that morning.

With the impressive results and detailed ASCO data representing a near-term stock catalyst, we reiterate our OP rating on IMRX.

The bottom line: On first blush, we come away very impressed by the new mOS data for atebi. In broader context, yes, we acknowledge the new efficacy bars that have been set by RVMD's dara in PDAC, data which come from later stage studies; that said, at this point, we favor atebi's clear edge on tolerability, and recently reported ctDNA data on acquired alterations (LINK) support atebi's resistance-sparing profile for 2L RAS inhibitor use, which help to maintain atebi's potential 1L opp'y.
With this mind, seeing a stock catalyst with new ASCO data, and favorable risk/reward, we stay OP-rated on IMRX.

1:51 - 1:57 PM CDTResults from a phase 2a study of atebimetinib in combination with mGnP in advanced or metastatic pancreatic cancer.Peter Vu, MD, MHAUniversity of California San DiegoAbstract 4013

https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17142

Leverage is low, with long-term debt near $3.3M and a current ratio above 17, indicating strong liquidity.

New Analyst Forecast: $IMRX Given $20 Price Target

https://www.quiverquant.com/news/New+Analyst+Forecast%3A+%24IMRX+Given+%2420+Price+Target

Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes

https://www.biospace.com/drug-development/can-revolutions-miracle-pancreatic-cancer-drug-be-topped-immuneering-actuate-say-yes

must read!
https://www.merlintrader.com/immuneering-corporation-may2026-deepdive/

The company still has a strong cash position and runway into 2029, which gives it time to push the platform forward without immediate financing pressure.


$RVMD $32B mkt cap vs IMRX $332M

HUGE: The only treatment-related adverse events observed at Grade 3 or higher in ≥10% of patients were anemia (16%) and neutropenia (18%), both chemotherapy-related.

IMRX...$6.79...🥳... Think its a $20 plus ticker...

georgie18

Re: georgie18 post# 284

Thursday, April 23, 2026 12:08:26 PM

Post#
286
of 288
IMRX...$6.03...🥳...

georgie18

Re: georgie18 post# 283

Tuesday, April 14, 2026 9:39:09 AM

Post#
284
of 285
IMRX...$5.86...🥳...$4.45 Average for me...Long Hold...Think its a $20 plus ticker...

georgie18

Re: georgie18 post# 276

Wednesday, March 25, 2026 10:21:06 AM

Post#
283
of 283
IMRX...$5.45...🥳...Bullish Psar Flip...

georgie18

Member Level
Re: georgie18 post# 274

Thursday, January 22, 2026 12:41:51 PM

Post#
276
of 282
IMRX...$5.24...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 712333

Thursday, January 22, 2026 9:55:50 AM

Post#
712373
of 712451
IMRX...$5.07...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 272

Thursday, January 22, 2026 8:19:57 AM

Post#
273
of 273
IMRX...$4.89...🥳

georgie18

Member Level
Re: georgie18 post# 711681

Wednesday, January 21, 2026 8:41:43 AM

Post#
712185
of 712332
IMRX...$4.76...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 268

Thursday, January 15, 2026 10:10:22 AM

Post#
270
of 271
IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see..

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

https://ir.immuneering.com/news-releases/news-release-details/immuneering-reports-173-months-median-overall-survival-first

Oral Presentation Details:
Title: Results from a phase 2a study of atebimetinib in combination with mGnP in advanced or metastatic pancreatic cancer
Session Type/Title: Rapid Oral Abstract Session – Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract Number: 4013
Date and Time: June 1, 2026, 1:15 p.m. – 2:45 p.m. CDT
Presenter: Peter Vu, MD, MHA

IMRX...$6.03...🥳...

georgie18

Re: georgie18 post# 283

Tuesday, April 14, 2026 9:39:09 AM

Post#
284
of 285
IMRX...$5.86...🥳...$4.45 Average for me...Long Hold...Think its a $20 plus ticker...

georgie18

Re: georgie18 post# 276

Wednesday, March 25, 2026 10:21:06 AM

Post#
283
of 283
IMRX...$5.45...🥳...Bullish Psar Flip...

georgie18

Member Level
Re: georgie18 post# 274

Thursday, January 22, 2026 12:41:51 PM

Post#
276
of 282
IMRX...$5.24...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 712333

Thursday, January 22, 2026 9:55:50 AM

Post#
712373
of 712451
IMRX...$5.07...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 272

Thursday, January 22, 2026 8:19:57 AM

Post#
273
of 273
IMRX...$4.89...🥳

georgie18

Member Level
Re: georgie18 post# 711681

Wednesday, January 21, 2026 8:41:43 AM

Post#
712185
of 712332
IMRX...$4.76...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 268

Thursday, January 15, 2026 10:10:22 AM

Post#
270
of 271
IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see..

The use of ctDNA in the development of cancer therapeutics is brilliant. Using DNA sequencing to provide data on biomarkers then a routine liquid biopsy like VolitionRX provides will quantify therapeutic treatment results quickly. Kudos to the team at IMRX. It's helping to cover some the A$$ets that VNRX destroyed. Ouch!

IMRX...$5.86...🥳...$4.45 Average for me...Long Hold...Think its a $20 plus ticker...

georgie18

Re: georgie18 post# 276

Wednesday, March 25, 2026 10:21:06 AM

Post#
283
of 283
IMRX...$5.45...🥳...Bullish Psar Flip...

georgie18

Member Level
Re: georgie18 post# 274

Thursday, January 22, 2026 12:41:51 PM

Post#
276
of 282
IMRX...$5.24...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 712333

Thursday, January 22, 2026 9:55:50 AM

Post#
712373
of 712451
IMRX...$5.07...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 272

Thursday, January 22, 2026 8:19:57 AM

Post#
273
of 273
IMRX...$4.89...🥳

georgie18

Member Level
Re: georgie18 post# 711681

Wednesday, January 21, 2026 8:41:43 AM

Post#
712185
of 712332
IMRX...$4.76...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 268

Thursday, January 15, 2026 10:10:22 AM

Post#
270
of 271
IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see..

IMRX...$5.45...🥳...Bullish Psar Flip...

georgie18

Member Level
Re: georgie18 post# 274

Thursday, January 22, 2026 12:41:51 PM

Post#
276
of 282
IMRX...$5.24...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 712333

Thursday, January 22, 2026 9:55:50 AM

Post#
712373
of 712451
IMRX...$5.07...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 272

Thursday, January 22, 2026 8:19:57 AM

Post#
273
of 273
IMRX...$4.89...🥳

georgie18

Member Level
Re: georgie18 post# 711681

Wednesday, January 21, 2026 8:41:43 AM

Post#
712185
of 712332
IMRX...$4.76...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 268

Thursday, January 15, 2026 10:10:22 AM

Post#
270
of 271
IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see...

Cool axel, and for those that missed the dip another opp before this thing gets back to it's happy place - much higher.

64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;
On track for expanded pancreatic cancer cohort data readout in first half of 2026 -

- On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 -

- Dosing in Phase 2 trial of atebimetinib + Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 -

- Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 -

https://ir.immuneering.com/news-releases/news-release-details/immuneering-reports-fourth-quarter-and-full-year-2025-financial

Sanofi bought 2,708,559 shares of Immuneering for about $18.96 million in Q3, making IMRX its 5th largest holding (˜7.3% of Sanofi’s portfolio) and representing a 6.52% ownership stake in the company.
Insiders have been buying stock recently — directors Peter Feinberg and Thomas Schall purchased 20,000 and 21,645 shares at ~$4.35 and ~$4.67 respectively, with insiders acquiring 51,819 shares (~$234k) in the past three months and now owning 22.90% of the company.
Market and analyst view: IMRX trades around $4.63 (down 4.9%), market cap ˜ $299M, while analysts give a consensus “Moderate Buy” with an average price target of $16.50; the company is a clinical-stage AI-driven biotech with lead program IRX-2 in Phase 2.
MarketBeat previews the top five stocks to own by March 1st.

"50-100% near term"

BinaryLogic
$IMRX [Read] Honestly-read the latest test results, compare the data to the current competitive set (favorable tolerability and superior performance at all test intervals), review the timeline to phase-III mid-2026 and ultimately to FDA/EMA approval where successful. The Company has $228M in Cash/ST against $13M Total Liabilities, equating to a Cash runway of more than 4YR using trailing burn rate (2022-25). Look at the 1YR Daily chart, and you will see that $4.4-4.8 is an interesting band in the progression. 16% SI here and if you are wondering why $5.0 did not hold today, you need only cross-reference the SI and the Options Chain. At the close of September, Sanofi provided $25M to IMRX in a private placement with $9.23 strike, and it was no coincidence (IMO) then to see the SP bottom at/around $4.62, or exactly 50% removed from that placement and mid-way between the support band on the 1YR Daily. 50-100% upside from this level (IMO) near term.
https://stocktwits.com/BinaryLogic/message/641294136

Stellar after hours performance.. I think someone said target of $18 in a few whatever..
$IMRX

$IMRX.. this is very good progress indeed!.. 🤑🥳

IMRX...$5.24...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 712333

Thursday, January 22, 2026 9:55:50 AM

Post#
712373
of 712451
IMRX...$5.07...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 272

Thursday, January 22, 2026 8:19:57 AM

Post#
273
of 273
IMRX...$4.89...🥳

georgie18

Member Level
Re: georgie18 post# 711681

Wednesday, January 21, 2026 8:41:43 AM

Post#
712185
of 712332
IMRX...$4.76...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 268

Thursday, January 15, 2026 10:10:22 AM

Post#
270
of 271
IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see...

Insiders love their own stock
$IMRX

IMRX...$5.07...🥳...Beauty move off the $4 range bottom... $4.45 average for me...

georgie18

Member Level
Re: georgie18 post# 272

Thursday, January 22, 2026 8:19:57 AM

Post#
273
of 273
IMRX...$4.89...🥳

georgie18

Member Level
Re: georgie18 post# 711681

Wednesday, January 21, 2026 8:41:43 AM

Post#
712185
of 712332
IMRX...$4.76...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 268

Thursday, January 15, 2026 10:10:22 AM

Post#
270
of 271
IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see...

IMRX...$4.89...🥳

georgie18

Member Level
Re: georgie18 post# 711681

Wednesday, January 21, 2026 8:41:43 AM

Post#
712185
of 712332
IMRX...$4.76...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 268

Thursday, January 15, 2026 10:10:22 AM

Post#
270
of 271
IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see...

IMRX...$4.76...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 268

Thursday, January 15, 2026 10:10:22 AM

Post#
270
of 271
IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see...

... at prices ranging from $4.57 to $4.571. 🤔

IMRX...$4.66...🥳

georgie18

Member Level
Re: georgie18 post# 711552

Wednesday, January 14, 2026 2:34:45 PM

Post#
711597
of 711680
IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see...

Looking real nice here G - Way to stick with this one. Timelines are impossible to predict I know...but it's still fun prognosticating. 16-20.00 taking 6 months or much longer...that's the question. No question it's moving up. Incredible pipeline.

IMRX...$4.42...🥳...Reversing Nicely...off the $4.03 Bottom...

georgie18

Member Level
Re: georgie18 post# 266

Wednesday, January 14, 2026 12:03:43 PM

Post#
267
of 267
IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see...

IMRX...Added $4.20s...🥳...Own from $4.20 to $5.45... This is $18 plus imo...we shall see...

IMRX...$4.83...🥳...My $4.65s look better my $5.45 not so much but this is an accumulation and hold stock...

me neither George!!!

IMRX...$4.65...🥳...Added here...In December 2025, Immuneering reiterated that its current cash and cash equivalents, based on current operating plans, are sufficient to fund operations into 2029.

georgie18

Member Level
Re: georgie18 post# 251

Thursday, January 08, 2026 9:49:03 AM

Post#
254
of 262
IMRX...$5.45...🥳...Loading the dip...

georgie18

Member Level
Re: georgie18 post# 249

Wednesday, January 07, 2026 4:08:51 PM

Post#
252
of 252
IMRX...$7.00...🥳...Bouncing off the quick dip...

georgie18

Member Level
Re: georgie18 post# 249

Wednesday, January 07, 2026 4:05:19 PM

Post#
250
of 250
IMRX...$6.20...🥳...Got some on the dip... https://finviz.com/news/269899/immuneering-announces-exceptional-64-overall-survival-at-12-months-in-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp

IMRX...$4.65...🥳...Added here...

georgie18

Member Level
Re: georgie18 post# 251

Thursday, January 08, 2026 9:49:03 AM

Post#
254
of 262
IMRX...$5.45...🥳...Loading the dip...

georgie18

Member Level
Re: georgie18 post# 249

Wednesday, January 07, 2026 4:08:51 PM

Post#
252
of 252
IMRX...$7.00...🥳...Bouncing off the quick dip...

georgie18

Member Level
Re: georgie18 post# 249

Wednesday, January 07, 2026 4:05:19 PM

Post#
250
of 250
IMRX...$6.20...🥳...Got some on the dip... https://finviz.com/news/269899/immuneering-announces-exceptional-64-overall-survival-at-12-months-in-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp

Done loading, let's go lolz.. 🤑
IMRX$

Here’s a **clear, fact-based picture** of **Immuneering Corporation (NASDAQ: IMRX)** and its **cash burn / runway situation** — key to understanding whether it can make it into the new year *without another financing (i.e., dilutive raise)*.

---

## 🔎 Current Cash & Cash Burn

### **1) Historical cash burn & runway (pre-late 2025 financing)**

* In **2024**, IMRX burned about **$55 M** of cash from operations. ([SEC][1])
* Quarterly operating cash burn in early 2025 was roughly **$14–15 M per quarter** (~$56–60 M annually). ([SEC][2])
* Based on a **~$36 M cash balance as of early 2025**, that implied only **~8 months of runway** without additional financing. ([Sahm][3])

This early 2025 picture was **not enough to go into the new year without another raise** unless the company cut spending sharply or suddenly generated revenue — which it did not.

---

## 💰 **Major Equity Raises Changed the Situation**

Recent financing dramatically altered the runway calculation:

### **2) Large capital raises in mid/late 2025**

* IMRX raised significant equity capital in **August/September 2025**, including a **private placement and underwritten offerings**, with participation from strategic investors like Sanofi. ([Fintool][4])
* Multiple financial reporting tools now show **cash & equivalents around ~$227–228 M** as of late 2025. ([Accountable Finance][5])

This is a **game-changer**:

* With a historical annual cash burn near **~$50–60 M**, ~$228 M gives **roughly 4+ years of runway** if burn remains consistent. ([Accountable Finance][5])
* Third-quarter 2025 results and commentary suggest **runway into 2029** barring major changes. ([GuruFocus][6])

---

## 📊 **So, does it need a raise to make the new year?**

### **Before the 2025 raises**

* **No —** cash on hand + burn rate *would not have been sufficient* to cover the entire 2025–2026 period without another raise. ([SEC][2])

### **After the 2025 raises**

* **Yes —** the company *now* appears to have enough runway through multiple years (beyond 2026) **without immediate additional financing**, assuming it manages expenses at typical levels. ([Accountable Finance][5])
* This means **no near-term orchestrated capital raise may be needed strictly for cash purposes**, as long as the burn rate doesn’t accelerate materially.

---

## ⚠️ **Important Risks & Caveats**

* IMRX still **has no product revenue**, so it is entirely dependent on financing and partnerships. ([Nasdaq][7])
* Clinical R&D is expensive and unpredictable — if programs expand or face delays, burn could accelerate.
* Runway estimates assume relatively stable spend; **unexpected costs could shorten it**.

---

## 📌 **Bottom Line**

✅ **Before the 2025 financing**, IMRX’s burn and cash balance *would not have carried it comfortably through a full year ending in 2026 without a raise.* ([Sahm][3])

✅ **After the mid-to-late 2025 capital raises**, IMRX now appears to have a **multi-year cash runway** (into 2029) at its historical burn rate, making short-term cash raises *not immediately necessary* solely for keeping operations going. ([Accountable Finance][5])

---

If you’d like, I can walk through how to estimate runway yourself (step-by-step), or calculate a more precise forecast based on different burn scenarios.

[1]: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000042/imrx-20241231.htm?utm_source=chatgpt.com "imrx-20241231"
[2]: https://www.sec.gov/Archives/edgar/data/0001790340/000179034025000061/imrx-20250331.htm?utm_source=chatgpt.com "imrx-20250331"
[3]: https://www.sahmcapital.com/news/content/heres-why-immuneering-nasdaqimrx-must-use-its-cash-wisely-2025-07-01?utm_source=chatgpt.com "Here's Why Immuneering (NASDAQ:IMRX) Must Use Its Cash Wisely"
[4]: https://fintool.com/app/research/companies/IMRX/earnings/Q2%202025?utm_source=chatgpt.com "Immuneering Corp (IMRX) Q2 2025 Earnings Summary | Fintool"
[5]: https://accountable.finance/stock/IMRX?utm_source=chatgpt.com "Immuneering Corp (IMRX) Stock: Fundamentals & Strategy Insights | Accountable Finance"
[6]: https://www.gurufocus.com/news/3204880/imrx-expects-cash-reserves-to-sustain-operations-through-2029?utm_source=chatgpt.com "IMRX Expects Cash Reserves to Sustain Operations Through 2029"
[7]: https://www.nasdaq.com/articles/immuneering-posts-narrower-loss-q2?utm_source=chatgpt.com "Immuneering Posts Narrower Loss in Q2 | Nasdaq"

Lot's of sp action, potential clinically with phase 3 trials ahead and the sudden drop I assume was yesterday's 8k which looks undramatic, perfect ingredients! lol

Thanks for the tip 🙂
IMRX$
https://www.nasdaq.com/market-activity/stocks/imrx/advanced-charting?timeframe=6m

Been on this from $1...This will be a $18 plus ticker...imo... we shall see...

Now we watch 🤑

Buying opportunity...🥳

Market really didn't like the results 8k but lots in the pipeline:

The Company expects the following near-term anticipated milestones related to atebimetinib:

•Presenting further updated circulating tumor DNA data on acquired alterations from cancer patients treated with atebimetinib at a major scientific meeting, in the second quarter of 2026.
•Announcing further updated survival data from over 50 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in the Company’s ongoing Phase 1/2a clinical trial, in the first half of 2026.
•Dosing the first patient in a pivotal Phase 3 clinical trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients, in mid-2026.
•Dosing the first patient in a clinical trial of atebimetinib in combination with Libtayo® in non-small cell lung cancer patients, in the second half of 2026.

edit

sorry, was supposed to be a post to no one 🙃

I never short stocks...🥳

for a short position? the chart looks mouth watering for a short

IMRX...$5.45...🥳...Loading the dip...

georgie18

Member Level
Re: georgie18 post# 249

Wednesday, January 07, 2026 4:08:51 PM

Post#
252
of 252
IMRX...$7.00...🥳...Bouncing off the quick dip...

georgie18

Member Level
Re: georgie18 post# 249

Wednesday, January 07, 2026 4:05:19 PM

Post#
250
of 250
IMRX...$6.20...🥳...Got some on the dip... https://finviz.com/news/269899/immuneering-announces-exceptional-64-overall-survival-at-12-months-in-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp

IMRX...$5.45...🥳...Loading the dip...

georgie18

Member Level
Re: georgie18 post# 249

Wednesday, January 07, 2026 4:08:51 PM

Post#
252
of 252
IMRX...$7.00...🥳...Bouncing off the quick dip...

georgie18

Member Level
Re: georgie18 post# 249

Wednesday, January 07, 2026 4:05:19 PM

Post#
250
of 250
IMRX...$6.20...🥳...Got some on the dip... https://finviz.com/news/269899/immuneering-announces-exceptional-64-overall-survival-at-12-months-in-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp